Literature DB >> 10203572

Mdm2: the ups and downs.

T Juven-Gershon1, M Oren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10203572      PMCID： PMC2230410     

Source DB:  PubMed          Journal:  Mol Med        ISSN： 1076-1551            Impact factor:   6.354


× No keyword cloud information.
  104 in total

1.  Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis.

Authors:  V Marechal; B Elenbaas; L Taneyhill; J Piette; M Mechali; J C Nicolas; A J Levine; J Moreau
Journal:  Oncogene       Date:  1997-03-27       Impact factor: 9.867

2.  MDMX: a novel p53-binding protein with some functional properties of MDM2.

Authors:  A Shvarts; W T Steegenga; N Riteco; T van Laar; P Dekker; M Bazuine; R C van Ham; W van der Houven van Oordt; G Hateboer; A J van der Eb; A G Jochemsen
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

3.  The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.

Authors:  S N Jones; A T Sands; A R Hancock; H Vogel; L A Donehower; S P Linke; G M Wahl; A Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 4.  Mdm-2: "big brother" of p53.

Authors:  J Momand; G P Zambetti
Journal:  J Cell Biochem       Date:  1997-03-01       Impact factor: 4.429

5.  The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation.

Authors:  B Guerra; C Götz; P Wagner; M Montenarh; O G Issinger
Journal:  Oncogene       Date:  1997-06-05       Impact factor: 9.867

6.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

7.  Regulation of p53 stability by Mdm2.

Authors:  M H Kubbutat; S N Jones; K H Vousden
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

8.  Mdm2 promotes the rapid degradation of p53.

Authors:  Y Haupt; R Maya; A Kazaz; M Oren
Journal:  Nature       Date:  1997-05-15       Impact factor: 49.962

9.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

Authors:  K Lundgren; R Montes de Oca Luna; Y B McNeill; E P Emerick; B Spencer; C R Barfield; G Lozano; M P Rosenberg; C A Finlay
Journal:  Genes Dev       Date:  1997-03-15       Impact factor: 11.361

10.  Identification of novel mdm2 binding peptides by phage display.

Authors:  V Böttger; A Böttger; S F Howard; S M Picksley; P Chène; C Garcia-Echeverria; H K Hochkeppel; D P Lane
Journal:  Oncogene       Date:  1996-11-21       Impact factor: 9.867
View more
  41 in total

Review 1.  Upstream open reading frames as regulators of mRNA translation.

Authors:  D R Morris; A P Geballe
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Binding induced folding in p53-MDM2 complex.

Authors:  Hai-Feng Chen; Ray Luo
Journal:  J Am Chem Soc       Date:  2007-02-16       Impact factor: 15.419

3.  Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.

Authors:  Abhik Saha; Masanao Murakami; Pankaj Kumar; Bharat Bajaj; Karen Sims; Erle S Robertson
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

4.  Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.

Authors:  Qiang Fu; Guoqiang Zhang; Hongwei Chen; Youwei Zheng; Jing Cheng
Journal:  Tumour Biol       Date:  2013-08-03

5.  Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Authors:  Yangbing Li; Jiuling Yang; Angelo Aguilar; Donna McEachern; Sally Przybranowski; Liu Liu; Chao-Yie Yang; Mi Wang; Xin Han; Shaomeng Wang
Journal:  J Med Chem       Date:  2018-12-10       Impact factor: 7.446

6.  Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas.

Authors:  K Inoue; F Zindy; D H Randle; J E Rehg; C J Sherr
Journal:  Genes Dev       Date:  2001-11-15       Impact factor: 11.361

7.  Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.

Authors:  R Khosravi; R Maya; T Gottlieb; M Oren; Y Shiloh; D Shkedy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

8.  HDM2-binding partners: interaction with translation elongation factor EF1alpha.

Authors:  Rebecca Frum; Scott A Busby; Mahesh Ramamoorthy; Sumitra Deb; Jeffrey Shabanowitz; Donald F Hunt; Swati P Deb
Journal:  J Proteome Res       Date:  2007-03-21       Impact factor: 4.466

9.  Human Oncoprotein MDM2 Up-regulates Expression of NF-κB2 Precursor p100 Conferring a Survival Advantage to Lung Cells.

Authors:  Catherine Vaughan; Lathika Mohanraj; Shilpa Singh; Catherine I Dumur; Mahesh Ramamoorthy; Carleton T Garrett; Brad Windle; W Andrew Yeudall; Sumitra Deb; Swati Palit Deb
Journal:  Genes Cancer       Date:  2011-10

10.  Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Authors:  Sanjeev Shangary; Ke Ding; Su Qiu; Zaneta Nikolovska-Coleska; Joshua A Bauer; Meilan Liu; Guoping Wang; Yipin Lu; Donna McEachern; Denzil Bernard; Carol R Bradford; Thomas E Carey; Shaomeng Wang
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.